Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1Xin Miao, Suzette Girgis, Yuki Iwaki et al.|Targeted Oncology|2023Cited by 46
Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).Alfred L. Garfall, María‐Victoria Mateos, Hareth Nahi et al.|Journal of Clinical Oncology|2020Cited by 42
Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple MyelomaXin Miao, Honghui Zhou, Liviawati S. Wu et al.|Blood|2022Cited by 5